HUMIRA (adalimumab), anti-TNF-α immunosuppressant

•  HUMIRA has Marketing Authorisation in the treatment of non-infectious intermediate, posterior and panuveitis in adults who have had an inadequate response to corticosteroids, in patients in need of corticosteroid-sparing, or in whom corticosteroid treatment is inappropriate.
• Despite a moderate efficacy compared to placebo, the therapeutic contribution is minor in the treatment due to the lack of a clinically relevant comparator, long-term safety and efficacy data, and demonstration of an impact in terms of quality of life.

-